---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-098462"
form_type: "8-K"
ticker: "MOVE"
cik: "0001734750"
company_name: "Corvex, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:31:42.215950+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Movano Health reports Q3 operating loss $7.4M, ships 339 Evie Rings, reverse split completed

## Summary
- Operating loss of $7.4M in Q3 2024, improved from $9.1M loss in Q3 2023.
- Cash and equivalents at Sept 30, 2024: $11.3M.
- 1-for-15 reverse stock split executed Oct 29; Nasdaq bid price compliance regained Nov 12.
- EvieMED 510(k) review in final stage; complete response submitted late Oct for medical features.
- Entered agreement phase for Q1 2025 pilot program with large healthcare company using EvieMED.

## SEC filing metadata
- accession: 0001213900-24-098462
- form_type: 8-K
- ticker: MOVE
- cik: 0001734750
- company_name: Corvex, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1734750/000121390024098462/0001213900-24-098462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1734750/000121390024098462/ea0220897-8k_movano.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-098462
- JSON: https://secwatch.observer/filing/0001213900-24-098462.json
- Plain text: https://secwatch.observer/filing/0001213900-24-098462.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.